Official ESCRS | European Society of Cataract & Refractive Surgeons



Search Title by author or title

Squamous cell carcinoma of the ocular surface and its unusual course

Poster Details

First Author: G.Athanasopoulos GREECE

Co Author(s):    G. Balanikas   A. Lioura   D. Kapantais   D. Panagiotou   K. Boboridis   F. Topouzis     

Abstract Details


The purpose of this case report is to present the diagnosis, treatment and course of a conjunctival tumor that was excised twice due to relapse and eventually treated with topical Interferon A2b. In addition to the description of our case, we quote the current knowledge for similar conditions of the ocular surface.


1st Department of Ophthalmology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece


A 76-year-old patient attended the Outpatient Clinics and was diagnosed with conjunctival Ca. An excision was performed and, after the histological examination, conjunctival carcinoma from the squamous cell epithelium was diagnosed. After two months, the patient reported recurrence of the tumor, which was removed by complete resection and circumferential excision with concurrent application of cauterization and 5-FU. A 5-FU collyrium was administered along with dexamethasone. The patient, however, due to intolerance stopped the treatment resulting in a relapse. Thus we decided to apply injections of interferon A-2b solution at the periphery of the limbus, and collyrium from the same formulation.


The rapid deterioration in disease progression was dramatically inhibited, but the anatomic integrity and the visual function of the patient's eye were not restored. Since then, the patient has been closely monitored for any possible sign of the disease with continuous administration of interferon alfa-2b to date and depiction with the aid of imaging techniques (UBM, brain CT, ocular ultrasound).


The use of interferon A-2b according to the applied scheme should be considered in cases of ophthalmic carcinoma even after the tumor’s excision.

Financial Disclosure:


Back to Poster listing